Mixed
Network meta-analyses (NMA) provide superior clinical utility for diabetes management compared to standard pairwise meta-analyses by simultaneously comparing multiple treatments using both direct and indirect evidence.
When choosing between multiple diabetes medications (like SGLT-2 inhibitors, GLP-1 RAs, or finerenone), rely on Network Meta-Analyses (NMA) rather than single-trial results. NMAs allow you to compare all options simultaneously against standard care, revealing which drugs best reduce specific risks like heart failure or kidney disease for your patient's specific profile.
The use of network meta-analyses (NMA) can fill this need... NMAs combine direct and indirect evidence acquired from one or more common comparators to simultaneously compare multiple treatments in a single pooled analysis.
Why this rating
Based on a systematic review of 821 trials and 471,815 patients, graded using GRADE.
Source
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Antonio Ceriello et al. · Cardiovascular Diabetology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →